Tirzepatide Beats Semaglutide on Multiple Diabetes Goals

What Was Studied — and Why It Matters

Managing type 2 diabetes isn't just about blood sugar. Doctors also track blood pressure, cholesterol, and body weight because keeping all four in a healthy range dramatically lowers the risk of heart disease, kidney damage, and other serious complications. Two injectable medications — tirzepatide (Mounjaro) and semaglutide (Ozempic/Wegovy) — are among the most effective tools available today, but which one helps patients hit more of these targets at once? A new analysis of the large SURPASS-2 clinical trial set out to answer exactly that.

What the Researchers Did

Scientists reviewed data from 1,879 adults with type 2 diabetes who took part in the SURPASS-2 trial. Participants were randomly assigned to take either semaglutide (1 mg weekly) or one of three doses of tirzepatide (5 mg, 10 mg, or 15 mg weekly). After 40 weeks, researchers counted how many patients reached standard and intensive goals across four areas:

• Blood sugar (HbA1c): Standard goal below 7%; intensive goal below 6.5%
• Blood pressure: Standard below 140/90 mmHg; intensive below 130/80 mmHg
• LDL cholesterol: Standard below 1.8 mmol/L; intensive below 1.4 mmol/L
• Weight loss: Standard above 10% body weight lost; intensive above 15% lost

What They Found

Tirzepatide outperformed semaglutide across the board. When looking at standard targets, only 34% of semaglutide users hit three or more goals — compared to 42%, 53%, and 57% of patients on tirzepatide 5 mg, 10 mg, and 15 mg, respectively. The gap was even wider for intensive targets: just 8% of semaglutide users met three or more intensive goals, versus up to 29% on the highest tirzepatide dose.

Tirzepatide was especially stronger for blood sugar control and weight loss. Patients on tirzepatide were nearly twice as likely to hit the standard blood sugar target and almost four times as likely to lose more than 15% of their body weight compared to those on semaglutide.

What This Means for Patients

If you and your doctor are considering a GLP-1 medication, this research suggests tirzepatide may offer an edge — especially if you need to lose significant weight or bring your HbA1c down closer to normal levels. That said, both medications are powerful options, and the best choice depends on your individual health history, insurance coverage, and how your body responds.

For patients already managing diabetes with injectable therapies, staying consistent with your routine matters just as much as which medication you use. Having reliable access to supplies — from pen needles to glucose monitoring tools — supports that consistency. MDS Diabetes offers a wide range of diabetes management supplies to help keep your routine on track.

Important Caveats

This was a post hoc analysis, meaning it looked back at existing trial data rather than being designed from the start to answer this specific question. Longer studies are still needed to confirm whether tirzepatide's advantages translate into fewer heart attacks, strokes, or other long-term complications.

Bottom Line

Tirzepatide helped significantly more type 2 diabetes patients reach multiple health targets — including blood sugar, weight, and blood pressure — compared to semaglutide over 40 weeks. If you're discussing medication options with your care team, this study gives you meaningful data to bring to that conversation.